Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Grand Pharmaceutical Group Limited ( (HK:0512) ) has shared an announcement.
Grand Pharmaceutical Group Limited announced the completion of patient enrollment and dosing for its Phase III clinical trial of TLX591-CDx, a diagnostic radiopharmaceutical for prostate cancer, in China. The New Drug Application is scheduled for submission this year, marking significant progress in the company’s nuclear medicine segment. The product, already commercialized in multiple countries, is expected to enhance the company’s market position and provide integrated diagnosis and treatment solutions for prostate cancer in China.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited operates in the pharmaceutical industry, focusing on innovative nuclear medicine for anti-tumor diagnosis and treatment. The company develops and commercializes radionuclide-drug conjugates and has a strong market presence in Mainland China, Hong Kong SAR, Macau SAR, and Taiwan Region.
Average Trading Volume: 11,595,954
Technical Sentiment Signal: Buy
Current Market Cap: HK$26.52B
Learn more about 0512 stock on TipRanks’ Stock Analysis page.